Cardio Diagnostics vs Virax Biolabs
CDIO and VRAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CDIO and VRAX compare
Virax Biolabs keeps more of each dollar of sales as profit, with a net margin of −40439% compared with −42722% at Cardio Diagnostics.
Virax Biolabs scores higher on the StockData Score (9 against 4 for Cardio Diagnostics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CDIO | VRAX |
|---|---|---|
| Size and price | ||
| Market cap | $5.7M | – |
| Share price | $1.92 | $0.627 |
| Change, 1 year | −50.3% | −94.6% |
| Beta (5Y) | 2.65 | 1.63 |
| Employees | 7 | – |
| StockData Score | ||
| Total score | 4 | 9 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 1 | 1 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 374× | – |
| P/B | 1.0× | – |
| FCF yield | −102% | – |
| Growth | ||
| Revenue growth (TTM) | – | 96.2% |
| Revenue growth, 5Y average | – | −36.9% |
| Profitability | ||
| Gross margin | – | 61.9% |
| Operating margin | −42650% (better) | −51515% |
| Net margin | −42722% | −40439% (better) |
| FCF margin | −38091% (better) | −39264% |
| Return on equity | −93.5% | −75.7% (better) |
| Return on invested capital | −136% (better) | −388% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −564.9× | – |
| Current ratio | 17.44 (better) | 9.97 |
| Altman Z-score | −1.27 | – |
| Piotroski F-score | 2 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 24.3% | 0.00% |
| Held by insiders | 2.7% | 63.6% |
| Short interest, % of float | – | 3.2% |
Go deeper
- CDIO stock overview
- CDIO income statement
- CDIO valuation and score
- VRAX stock overview
- VRAX income statement
- VRAX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.